Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
[ad_1] CFOTO | Future Publishing | Getty Images Pfizer on Friday said it would stop developing the twice-daily version of its experimental weight loss pill after obese patients taking the drug lost weight but had trouble tolerating the drug in a mid-stage clinical study. The drugmaker observed high rates of adverse side effects, which were…